9 completed, 6 not yet recruiting, 4 recruiting, 1 unknown. 10 Phase 1, 6 Phase 2, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 6, Not yet recruiting 2, Recruiting 2 |
| Phase 2 | 6 | Not yet recruiting 2, Recruiting 2, Completed 1, Unknown 1 |
| Phase 3 | 6 | Not yet recruiting 3, Completed 2, Recruiting 1 |
Follow Onconic Therapeutics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects JP-1366 20 mg, Lansoprazole 30 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg, Lansoprazole 30mg, JP-1366 20 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg - H. Pylori Eradication Therapy | Phase 3 | Not yet recruiting | Onconic Therapeutics Inc. | 414 | 2026-11-01 | 2026-10-15 |
| Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis JP-1366 10 mg, Lansoprazole 15mg - Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD) | Phase 3 | Not yet recruiting | Onconic Therapeutics Inc. | 384 | 2026-08-01 | 2026-07-28 |
| Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants JPI-547 - Healthy Volunteers | Phase 1 | Not yet recruiting | Onconic Therapeutics Inc. | 36 | 2026-05-01 | 2026-05-06 |
| To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer JPI-547, Irinotecan (drug) - Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Onconic Therapeutics Inc. | 49 | 2026-02-27 | 2026-01-23 |
| To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer JPI-547, Bevacizumab - Ovarian Cancer | Phase 2 | Not yet recruiting | Onconic Therapeutics Inc. | 81 | 2026-02-27 | 2026-01-27 |
| to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban JP-1366 and clopidogrel, JP-1366 and aspirin, JP-1366 and atorvastatin - Drug Drug Interaction (DDI) | Phase 1 | Recruiting | Onconic Therapeutics Inc. | 96 | 2025-11-17 | 2025-12-04 |
| Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease JP-1366 + placebo, Placebo + Placebo - Non-erosive Gastroesophageal Reflux Disease | Phase 3 | Not yet recruiting | Onconic Therapeutics Inc. | 321 | 2025-09-02 | 2025-09-08 |
| Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers JLP-2302, JP-1366 - Healthy | Phase 1 | Completed | Onconic Therapeutics Inc. | 55 | 2025-02-04 | 2025-09-18 |
| Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers JP-1366 10 mg, Lanston Capsule 15 mg, JP-1366 10 mg placebo - Peptic Ulcer | Phase 3 | Recruiting | Onconic Therapeutics Inc. | 364 | 2024-10-22 | 2024-11-01 |
| First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer Nesuparib, Pembrolizumab - Endometrial Cancer, Recurrent Endometrial Carcinoma | Phase 2 | Recruiting | Yonsei University | 92 | 2024-09-12 | 2025-04-03 |
| Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers JP-1366 20mg tablet - Healthy | Phase 1 | Completed | Onconic Therapeutics Inc. | 24 | 2023-03-29 | 2024-08-26 |
| Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers JP-1366 20mg tablet, JP-1366 20mg capsule - Healthy | Phase 1 | Completed | Onconic Therapeutics Inc. | 30 | 2022-09-30 | 2023-04-20 |
| Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer JP-1366 20mg, Lansoprazole 30mg - Gastric Ulcer | Phase 3 | Completed | Onconic Therapeutics Inc. | 329 | 2022-09-19 | 2024-08-26 |
| A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor JPI-547 - Ovarian Cancer | Phase 2 | Unknown | Onconic Therapeutics Inc. | 58 | 2022-08-31 | 2024-08-27 |
| Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Onconic Therapeutics Inc. | 71 | 2022-03-30 | 2026-04-13 |
| JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis JP-1366 20mg, Esomeprazole 40mg - Erosive Esophagitis | Phase 3 | Completed | Onconic Therapeutics Inc. | 300 | 2022-01-17 | 2024-08-27 |
| Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian coadministration of JP-1366 and aceclofenac, coadministration of JP-1366 and meloxicam, coadministration of JP-1366 and naproxen - Anti-Ulcer Agents | Phase 1 | Completed | Onconic Therapeutics Inc. | 88 | 2021-03-05 | 2022-06-30 |
| Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers JP-1366 20mg 1capsule, Amoxicillin 500Mg Cap, Clarithromycin 500Mg Tab - Helicobacter Pylori Associated Gastrointestinal Disease | Phase 1 | Completed | Onconic Therapeutics Inc. | 29 | 2020-11-18 | 2022-01-18 |
| Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease JP-1366, JP-1366 placebo, Esomeprazole 40mg - GERD | Phase 2 | Completed | Onconic Therapeutics Inc. | 188 | 2019-11-15 | 2022-07-13 |
| A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors JPI-547 - Advanced Solid Tumors | Phase 1 | Completed | Onconic Therapeutics Inc. | 62 | 2017-12-06 | 2022-06-03 |
Ovarian Neoplasms (2) · Endometrial Neoplasms (1) · Gastroesophageal Reflux (1) · Non-Erosive Reflux Disease (1) · Peptic Ulcer (1) · Stomach Neoplasms (1) · Stomach Ulcer (1)
Lansoprazole (3) · Amoxicillin (2) · Clarithromycin (2) · Esomeprazole (2) · Tablets (2) · Aspirin (1) · Atorvastatin (1) · Bevacizumab (1) · Capsules (1) · Clopidogrel (1) · Irinotecan (1) · Meloxicam (1) · Naproxen (1) · Pharmaceutical Preparations (1) · aceclofenac (1)
South Korea (17)